治疗慢性心力衰竭的医疗疗
1Monash Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, VIC, Australia.
Lancet (London, England)
|August 23, 2011
概括
慢性心力衰竭的药理疗法正在发展,新的临床试验发现扩大了现有治疗方法的作用,并挑战了旧的算法. 新的方法为心力衰竭管理提供了令人兴奋的未来可能性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 慢性心力衰竭管理是一个充满活力的领域.
- 当代药理疗法不断通过临床证据进行更新.
研究的目的:
- 审查慢性心力衰竭的药理疗法的不断变化的格局.
- 讨论临床试验结果如何影响当前的治疗策略.
- 突出新的治疗方法和未来的方向.
主要方法:
- 审查最近的临床试验和药理学研究.
- 分析最新的治疗指南和算法.
- 在心力衰竭中综合新兴的治疗概念.
主要成果:
- 根据新的数据,心力衰竭的既定疗法已经扩大了其作用.
- 之前的治疗算法受到最近临床试验结果的挑战.
- 试验调查心力衰竭与保存的喷射分数产生混合的结果,与正在进行的研究.
结论:
- 慢性心力衰竭的药理疗法正在经历重大转变.
- 新的治疗策略正在出现,呈现出有前途的未来选择.
- 对临床试验数据的持续评估对于优化心力衰竭护理至关重要.
相关概念视频
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

